Navigation Links
NEURO-BIOTECH CORPORATION: Updates and latest developments

NEURO-BIOTECH CORPORATION: Updates and latest developments

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
OTC, SmallCap, Biotechnology Click to view news release full screen  

NEURO-BIOTECH CORPORATION: Updates and latest developments


BASEL, Switzerland, Nov. 1 /PRNewswire/ - Neuro-Biotech Corporation (PINKSHEET: MRES) (OTCQB: MRES).

In the first "Update to Shareholders," we advised shareholders of the Company's new direction as well as the list of licensed products ready to be manufactured and distributed.

Subsequently, we revealed the description of two "Blood Tests" by first releasing a scientific account and analysis followed by a "layman's" version with explanations for common understanding.

We have also informed the public, based on official statistics, of the commercial potential of the SymPath test in the American market.

It is now the time to disclose the work done since the first "Update to Shareholders."

Neuro-Biotech has to date, signed confidentiality agreements with various interested parties, including a Spanish group representing the vast majority of hospitals and private clinics in Spain. This group has shown a particular appreciation for the distribution of all our blood tests. Seeing that there is language and historical ties, all private clinics and private hospitals located in South America will be automatically granted access.

Now if you review the list of licenses your company owns, you will notice that the last four licenses (13, 14, 15, 16), are what we call Neuroceuticals™. It's actually tablets to be sold in pharmacies, that will be classified and sold as "food supplements," in order to accelerate the market penetration. There will be two concentrations; one sold "over the counter," and the other with a medical prescription.

This fact is mentioned due to the ongoing actual negotiations with another Spanish party that controls networks of pharmacies across the country and in South America. Very soon, similar negotiations will open with large chains of pharmacies in the United States and Canada.

We already have on hand a first order from Egypt, and we expect to conclude and receive other sales orders in the near future. The manufacturing of these tablets do not require significant capital investments such as laboratories. Fabrication will be assigned to a pharmaceutical company, already identified, responding to all our criteria and quality standards. As for cost, it remains for us to agree on the quantities to achieve economies of scale.

Regarding our "Blood Tests," we also started preliminary discussions with chains of laboratories, in order to first, identify, evaluate and explore potential partnerships. This will avoid us having to invest in our own lab facilities in the short and medium term while ensuring the production of blood test results for health professionals to track their patients. This is exactly the same principle as a blood test ordered by your doctor to know your cholesterol levels.

We also solicited and were contacted by various insurance companies about "SymPath." This test has been the subject of numerous scientific publications and has been evaluated in over 5,000 human subjects with consistent results of 98.8% precision. With this accuracy, the results could be enough to obtain a legal court opinion on a patient's medical status.

The reason why insurance companies have expressed such a considerable interest is economic. As this test accurately measures the patient's condition on a scale, it avoids the sequences of "trial and error," as is currently the case in the beginning of treatment. Therefore, the health professional receiving the test results will immediately be able to precisely diagnose the patient's condition and to prescribe the proper medication.

The immediate consequences, as you can imagine, will be a dramatic reduction of suffering for the patient, his family, his environment and accelerated healing. From a purely economic and social development standpoint, this will certainly lead to a significant reduction in lost workdays, and fewer payments from insurers and employers! Currently, without this test, it is virtually impossible for medical professional specializing in this type of disease, to separate the real from the fake patients. The whole of society will benefit from this.

The Company will continue to provide its shareholders and investors with timely updates.

For more information, do not hesitate to contact us by using the form on our corporate website at Your request will be transferred to the appropriate person and we will get back to you as soon as possible. Forward Looking Statements This release contains statements that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Act of 1995. Certain statements in this press release may contain words such as "anticipates," "believes," "could," "expects," "intends," "may," "projects," "targets" and other similar language that is considered forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties and persons reading this release are cautioned that such statements are only predictions, and that the Company's actual future results or performance may be materially different. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events, or otherwise, could cause the company's actual results to differ materially from those indicated in any forward-looking statements.

CONTACT: <p>Neuro-Biotech Corp.<br/> Dr Claude Poulin<br/> 41 61 500 05 16<br/> <a href=""></a><br/> <a href=""></a></p>

SOURCE Neuro-Biotech Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

2. Neuro-Biotechs Solution for a Doctor near You: Early Detection for Alzheimers and Chronic Fatigue Syndrome!
3. Mr Claude Poulin nominated as President and CEO of Neuro-Biotech Corp.
4. Guy J. Quigley Resigns as Chairman and CEO of The Quigley Corporation: Quigley Leaves Company He Founded 20 Years Ago
5. China Cord Blood Corporation Updates Status Regarding Share Repurchase Program
6. Cord Blood America CEO Updates Investors on Financial Developments and Stem Cell News in Interview
7. China-Biotics Provides Further Updates on Qingpu New Facility
8. Yongye International Expands Its Existing Production Capacity by 50% and Provides Updates on Customer List Acquisition
9. China-Biotics Provides Updates on Qingpu New Facility and Chinese Probiotics Market
10. BioMS updates corporate strategy and adds leading healthcare investment banker
11. BioMS Medical updates University of Alberta equity position
Post Your Comments:
(Date:10/8/2015)... 2015 .   ... Goldman Small Cap Research, a stock market ... microcap sectors, announced today that it has published ... Inc. (OTCQB - PMCB), a publicly traded, clinical ... treatments for cancer and diabetes. To view the ...
(Date:10/8/2015)...  The ALS Association, in partnership with Prize4Life, is ... revolutionize communication technology solutions for people living with ALS. ... (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that ... spinal cord. Eventually, people with ALS lose the ability ... to total paralysis and death within two to five ...
(Date:10/8/2015)... ... , ... Talon Innovations, a provider of Precision Machined Products and ... is one of three finalists for the Minnesota Business magazine’s Manufacturing Award in the ... Innovations was recognized as a nominee for this competitive award. , The “Best ...
(Date:10/7/2015)... , Oct. 7, 2015 Boston ... the start of the Boston Scientific Connected Patient ... advancements in the use of remote patient monitoring to ... designers and entrepreneurs can submit their ideas and collaborate ... ( ). Cambridge, MA ...
Breaking Biology Technology:
... , ... , Formation of new blood ... been the focus of many drug screening and cell signaling research studies. Blood ... tumors, and is implicated in wound healing, retinopathy and macular degeneration. , ...
... , Tran T. Nham Varian Australia ... Introduction , Because ... with an ICP spectrometer, it has been widely used to determine trace ... work was to evaluate the ability of the ultrasonic nebulizer to handle ...
... Varian, Inc. , Introduction ... are veterinary drugs. The use of these in food production is ... and the European Union because of a possible increased cancer-risk through ... of nitrofurans contamination has been found in warm-water prawns, shrimp, and ...
Cached Biology Technology:
(Date:9/10/2015)... LONDON , Sept. 10, 2015 This ... dominate wearable technology products today, and emerging sensor types ... have risen through the peak of the wearable technology ... the slide to disillusionment. The common feature with all ... the key enabler for their most useful functions. Sensors ...
(Date:9/9/2015)... Columbia , Sept. 9, 2015  NuData ... organizational and solution-based milestones, furthering the company,s commitment ... of online fraud. NuData Security,s online ... enhancing the company,s growth cycle. The product combines ... to determine good user behavior from fraudulent behavior, ...
(Date:9/2/2015)... California , September 2, 2015 ... the security purpose implied in a system which ... geometry, voice, signature, iris, vein, DNA and finger ... has forced to develop such system which provides ... username, password, PIN, Patterns and tokens are vulnerable ...
Breaking Biology News(10 mins):
... MAMMALS could be at a greater risk of extinction due ... published today by the Zoological Society of London (ZSL). ... with information of where droughts and cyclones are most likely ... risk of exposure to extreme weather. The paper, published this ...
... WASHINGTON D.C. -- Secretary of Energy Steven Chu was among ... NSF,s Graduate Research Fellowship Program (GRFP) today. GRFP is ... engineering fields within NSF,s mission. It has been in ... in students with demonstrated potential for significant achievements in science ...
... synchronize their movements. For example, the footsteps of two ... consciously aware that it is happening. Similarly, the clapping ... Although this type of synchronous body movement has been ... social interactions remain obscure. In a new study, led ...
Cached Biology News:
... human XAB2 (amino terminus) XAB2 (XPA-binding ... interaction with XPA. Immunoprecipitation experiments have also ... with the transcription-coupled repair-specific proteins CSA and ... II. Microinjection experiments with XAB2 antibodies resulted ...
... maintenance, calibration, and validation (MCV) ... 96-well plate used for hands-free ... procedures using the Bio-Plex suspension ... is for use with Bio-Plex ...
Biology Products: